Bioretec Ltd Company announcement 22 December 2025 at 5:30 p.m. EET

TAMPERE, Finland, Dec. 22, 2025 /PRNewswire/ -- In 2025, Bioretec will publish the following financial reports:

financial statements bulletin for January-December 2025 on Friday 13 February 2025
annual report, Board of Directors' report and financial statements for 2025 on Friday 13 March 2026
business review for January-March 2026 on Thursday 14 May 2026
half-year report for January-June 2026 on Thursday 13 August 2026
business review for January-September 2026 on Thursday 12 November 2026

Financial reports will be published as company releases and will be available online on Bioretec Ltd's website at https://bioretec.com/investors/investors-in-english/reports-and-presentations

Bioretec Ltd's Annual General Meeting is planned to be held on Friday, 8 May 2026. The company's Board of Directors will convene the Annual General Meeting separately later.

Further enquiries

Sarah van Hellenberg Hubar-Fisher, CEO, +31 6 1544 8736

Certified Adviser

Nordic Certified Adviser AB, +46 70 551 67 29

About Bioretec

Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.

The company's latest innovation, the RemeOs™ product line, is based on a high-performance magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The first RemeOs product market authorization was received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025.

Bioretec's Activa product line features fully bioabsorbable orthopedic implants made from a proprietary, self-reinforced PLGA both CE marked and FDA cleared for a wide range of indications in adult and pediatric patients.

Bioretec is shaping the future of orthopedic treatment with a focus on healing through absorption, paving the way for more effective and patient-friendly solutions.

To learn more about Bioretec, visit www.bioretec.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bioretec/r/bioretec-ltd-s-schedule-for-financial-reporting-and-annual-general-meeting-in-2026,c4285851

View original content:https://www.prnewswire.co.uk/news-releases/bioretec-ltds-schedule-for-financial-reporting-and-annual-general-meeting-in-2026-302648145.html

Tags

More Like This

Bioretec Ltd's schedule for financial reporting in 2024 and updates in the disclosure policy

Bioretec Ltd's Annual Report 2024 published

Bioretec Ltd's Annual Report and Financial Statements 2023 published

Bioretec Ltd's Financial Statements 2024 published

Bioretec Ltd's Half-year report 2025: Strong support for future growth from a successful rights issue

Bioretec Ltd's financial statements bulletin 2023: Another successful year in the growth trajectory

Resolutions of Bioretec Ltd´s Annual General Meeting and the constitutive meeting of the Board of Directors

Bioretec Ltd's financial statements bulletin 2024: Foundation for future growth in 2024 - CE mark received in January 2025